Inflammatory Activity on Natalizumab Predicts Short-term but not Long-term Disability in Multiple Sclerosis - Raffel, J; Gafson, AR; Dahdaleh, S; Malik, O; Jones, B; nicholas, R (PLOS One, 2017)